RosTrace

Tag: antiviral development

Robin Hayes

ADC189: A Promising Single-Dose Oral Therapy for Influenza Emerges from Preclinical and Phase I Trials

Seasonal influenza continues to exact a heavy toll on global health, causing an estimated 3–5 million cases of severe illness and up to 650,000 respiratory deaths annually. Existing antivirals—principally neuraminidase inhibitors (such as oseltamivir) and M2 ion-channel blockers (amantadine and rimantadine)—have demonstrable limitations. Resistance to these agents has steadily increased, and their efficacy is often modest when administered more than 48 hours after symptom onset. Moreover, the logistical challenges of multi-dose regimens hinder public health efforts during epidemics and pandemics. There is therefore an urgent need for a novel, broadly active, single-dose antiviral that can both treat and prevent influenza, including resistant and pandemic strains.

· 4 min read

Robin Hayes

Investigating the F446L Mutation in Lassa Virus: Implications for Novel Therapeutics

This blog post explores the Lassa virus (LASV), its glycoprotein complex, and the implications of the F446L mutation on viral behavior and treatment strategies. With a focus on molecular biology and recent studies, we delve into how these findings can aid in the development of effective vaccines and therapeutics. Understanding these mutations is crucial for improving public health responses to Lassa fever, particularly in West Africa, where outbreaks are prevalent.

· 5 min read